Dr. Charles M. Farber, MD, PhD

Dr. Farber practices at Morristown Medical Center in Morristown, New Jersey, part of Atlantic Health System.

Dr. Farber's NPI, 1144218215, was assigned on October 12, 2005. Dr. Farber graduated from New York University School of Medicine in 1986. Dr. Farber holds New Jersey license 25MA06175000.

Dr. Farber's primary practice is Morristown Medical Center, at 100 Madison Ave, Morristown, NJ 07962 in Morris County. The practice phone is (973) 971-5450.

Dr. Farber's primary practice is Morristown Medical Center in Morristown, New Jersey, part of Atlantic Health System. Dr. Farber is also affiliated with Overlook Medical Center. The medical group on file is Atlantic Medical Group. Dmand AI also links Dr. Farber to 2 more hospitals and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Farber practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Farber's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Farber is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Farber's licenses on file in 3 states: New Jersey, Florida and New York.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, immune deficiency disease, lung cancer, lymphoma and multiple myeloma among the conditions Dr. Farber treats.

CMS data shows 3,024 Medicare services from Dr. Farber across 8 procedure codes in 2024, for 448 Medicare patients. Medicare paid $188,970 for them.

CMS counts 448 Medicare patients who saw Dr. Farber in 2024. The largest group is 75 to 84, with 209 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 1.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Farber's median patient age at 74, with 49% women.

In 2024, Dr. Farber wrote 173 Medicare Part D claims for 52 patients. 69% of them were for generic drugs. CMS names the drug for 103 of them, across 8 drugs with 11 or more claims each, at $459,922 in total drug cost. In 2023, CMS named 146 claims across 8 drugs.

Dr. Farber accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 39 papers to Dr. Farber, published from 2009 to 2025. 2017 was the busiest year, with 6. The most frequent topics are Leukemia, Lymphocytic, Chronic, B-Cell, Antineoplastic Combined Chemotherapy Protocols and Ascorbic Acid. Dr. Farber has published most often in Front Plant Sci. Dr. Farber's most frequent co-authors are Nicole Lamanna, MD, Matthew S. Davids, MD and David L. Grinblatt, MD.

Dmand AI links Dr. Farber to 20 clinical trials, 8 of them phase 3 studies. 10 are still active or recruiting. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, B-Cell and Lymphoma, Follicular. National Cancer Institute (NCI) sponsors the most, 4. Open Payments lists research payments to Dr. Farber that name 2 trials.

CMS Open Payments shows 2,033 general payments to Dr. Farber from 79 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 65% of the total. Incyte Corporation paid the most, $234,335. It also lists 23 research payments totaling $47,391 from 2016 to 2023, naming 2 clinical trials.

Dmand AI lists 6 awards for Dr. Farber, most recently Inside Jersey Magazine Top Doctors in 2014.

Dr. Farber graduated from New York University School of Medicine in 1986. Dr. Farber is a member of ASCO.

Dr. Farber is in network with 4 carriers, including Cigna, Horizon Blue Cross Blue Shield of New Jersey and Humana. Medicare plans come from the most carriers, 4. Check the plan with the practice before a visit.